SCHEMBL2697747

SCHEMBL2697747

CC(C)(c1ccccc1)N1CCCCC1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 0.53
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
MITF O75030 1/20 0.40
PER2 O15055 1/20 0.39
OPRM1 P35372 1/20 0.38
ACHE P22303 1/20 0.37
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2695770 0.95 CYP2B6 (0.50) CYP2B6ALDH1A1MAPTHSD17B10L3MBTL1
SCHEMBL29348785 0.83 SMN1; SMN2 (0.41) CYP2B6ALDH1A1MAPTSMN1; SMN2MITF
SCHEMBL29348754 0.83 HSD11B1 (0.43) CYP2B6ALDH1A1SMN1; SMN2MITFGAA
SCHEMBL31230458 0.82 ALDH1A1 (0.45) CYP2B6ALDH1A1MAPTHSD17B10L3MBTL1
SCHEMBL12581558 0.79 TSHR (0.38) ALDH1A1MAPTHSD17B10L3MBTL1SMN1; SMN2
SCHEMBL18910024 0.78 PER2 (0.42) CYP2B6ALDH1A1SMN1; SMN2MITFPER2
SCHEMBL20476032 0.78 KMT2A (0.39) CYP2B6ALDH1A1MAPTHSD17B10L3MBTL1
SCHEMBL8092347 0.77 HTT (0.41) CYP2B6ALDH1A1MAPTHSD17B10L3MBTL1
SCHEMBL9910032 0.73 CYP2B6 (0.42) CYP2B6ALDH1A1MAPTSMN1; SMN2OPRM1
SCHEMBL9910033 0.73 SMN1; SMN2 (0.45) CYP2B6ALDH1A1SMN1; SMN2PER2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US disclosed
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US disclosed
US-8088771-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 CYP2B6 2859/4885ALDH1A1 957/4885MAPT 1634/4885
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 CYP2B6 2859/4885ALDH1A1 957/4885MAPT 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.